Covid-19 roundup: Merck's pill sees heavy use; Moderna faces off against Pfizer in vaccine race for youngest kids
Merck’s new Covid-19 pill molnupiravir barely cleared an FDA advisory committee vote (13-10) on the way to its EUA.
And although the FDA and NIH said that the Ridgeback-partnered pill should only be used as a last resort due to concerns with its mechanism of action, the Wall Street Journal reported Monday that more than 74,700 prescriptions for the Merck-Ridgeback pill were filled through Feb. 25, according to IQVIA, while there were more than 79,150 prescriptions filled for the more effective Paxlovid.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
